---
aliases:
- (Peersmann et al., 2022)
author: Peersmann, Shosha H. M. and Grootenhuis, Martha A. and Van Straten, Annemieke
  and Tissing, Wim J. E. and Abbink, Floor and De Vries, Andrica C. H. and Loonen,
  Jacqueline and Van Der Pal, Helena J. H. and Kaspers, Gertjan J. L. and Van Litsenburg,
  Raphaële R. L.
citekey: peersmann2022InsomniaSymptomsDaytime
date_added: '2025-03-23'
doi: 10.3390/cancers14143316
journal: Cancers
title: 'Insomnia Symptoms and Daytime Fatigue Co-Occurrence in Adolescent and Young
  Adult Childhood Cancer Patients in Follow-Up after Treatment: Prevalence and Associated
  Risk Factors'
year: '2022'

---
# Insomnia Symptoms and Daytime Fatigue Co-Occurrence in Adolescent and Young Adult Childhood Cancer Patients in Follow-Up after Treatment: Prevalence and Associated Risk Factors
- [PDF Link](zotero://open-pdf/library/items/KBLVUGPN)

Citation: [@peersmann2022InsomniaSymptomsDaytime]

***
# TL;DR (Summary)
- 38.2% of patients reported insomnia and/or daytime fatigue symptoms.
- 48.1% of symptomatic patients reported both insomnia and daytime fatigue, 34.7% reported insomnia only, and 17.1% reported daytime fatigue only.
- Insomnia severity was higher in the insomnia-daytime fatigue group (mean ISI score 14.89) compared to the insomnia-only group (mean ISI score 11.41, p < 0.001).
- Utilized a large, heterogeneous national cohort to study the co-occurrence of insomnia and daytime fatigue in adolescent and young adult childhood cancer survivors.
- Employed a cross-sectional design to assess the prevalence and risk factors of insomnia and daytime fatigue, providing a comprehensive analysis of symptom subgroups.
- Authors suggest that healthcare providers should inquire about insomnia symptoms in patients with daytime fatigue, as this could provide additional treatment options.
- Future research should evaluate the effectiveness of adding insomnia monitoring and treatment to fatigue management strategies.
- The study highlights the common co-occurrence of insomnia and daytime fatigue in pediatric oncology groups after treatment, which is often overlooked in current fatigue guidelines.
- Identified modifiable sleep behaviors as significant risk factors, suggesting potential areas for intervention and prevention strategies.

# 中文摘要 (TL;DR)
- 38.2% 的患者報告了失眠和/或白天疲勞症狀。
- 48.1% 的有症狀患者同時報告了失眠和白天疲勞，34.7% 報告了僅失眠，17.1% 報告了僅白天疲勞。
- 失眠-白天疲勞組的失眠嚴重程度（平均 ISI 得分 14.89）高於僅失眠組（平均 ISI 得分 11.41，p < 0.001）。
- 利用大型、異質的全國性隊列研究青少年和年輕成人兒童癌症倖存者的失眠和白天疲勞的共現。
- 採用橫斷面設計評估失眠和白天疲勞的患病率和風險因素，提供了對症狀亞組的全面分析。
- 作者建議醫療提供者應詢問白天疲勞患者的失眠症狀，因為這可能提供額外的治療選項。
- 未來研究應評估將失眠監測和治療納入疲勞管理策略的有效性。
- 該研究強調了在治療後的兒科腫瘤組中，失眠和白天疲勞的常見共現，這在當前的疲勞指南中經常被忽略。
- 識別出可改變的睡眠行為是重要的風險因素，建議可能的干預和預防策略領域。
